Trials / Completed
CompletedNCT01062620
A Dose Escalating Clinical Trial of the IGF-1 Receptor Inhibitor AXL1717 in Patients With Advanced Cancer
A Dose Escalating Phase Ia-b Clinical Trial of the IGF-1 Receptor Inhibitor AXL1717 in Patients With Advanced Cancer: A Prospective, Single Armed, Open Label, Dose-finding Phase Ia-b Study
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 49 (actual)
- Sponsor
- Axelar AB · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
A dose escalating phase Ia-b clinical trial of the IGF-1 receptor inhibitor AXL1717 in patients with advanced cancer. The objective is to study the safety and pharmacokinetics of AXL1717 and to define an appropriate Phase 2 dose for further studies. This is the first study in man. The study is not designed to show tumor response.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | AXL1717 | Phase I study with increasing dosage and treatment duration |
Timeline
- Start date
- 2008-04-01
- Primary completion
- 2011-05-01
- First posted
- 2010-02-04
- Last updated
- 2011-09-15
Locations
1 site across 1 country: Sweden
Source: ClinicalTrials.gov record NCT01062620. Inclusion in this directory is not an endorsement.